In a bid to achieve 20% growth year-on-year, Natco Pharma is planning to launch around 8-10 new products in domestic branded formulations segment during FY18. The Hyderabad-based drug firm is also planning to maintain its leadership position in oncology and gastro hepatology segment during the year as part of its short-term growth plan.
Moreover, the company is looking at gaining traction in the newly launched cardiology and diabetology (CnD) division. The company is also planning to expand its Hepatitis-C product portfolio during the year.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: